Diets with different protein amounts in sarcopenia indices among patients with hepatic cirrhosis

Evaluation of the effect of diets with different protein amounts on sarcopenia indices in patients with hepatic cirrhosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100524004010N44

Enrollment

Registered

2026-05-09

Start date

2026-02-10

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sarcopenia in patients with hepatic cirrhosis. Other and unspecified cirrhosis of liver

Interventions

Intervention 1: Intervention group: A diet containing 32 kcal per body weight of energy and 1.5 g per body weight of protein. Intervention 2: Control group: Diet containing 32 kcal per body weight of

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years old Diagnosis of cirrhosis based on the opinion of a gastroenterologist and liver specialist Body mass index between 18.5 to 30 kg/m2 Ability to receive complete food and adhere to a prescribed diet Not taking Branched-Chain Amino Acids (BCAA) or Whey protein supplements three months prior to the study Normal kidney function

Exclusion criteria

Exclusion criteria: Increased creatinine levels above normal Hospitalization due to acute liver failure or severe infection Having any malignancy Alcohol consumption

Design outcomes

Primary

Measure	Time frame
Muscle Strength. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Dynamometer, walking test, chair sitting test.	—

Secondary

Measure	Time frame
Model for End-stage liver disease (MELD) score. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Calculation based on creatinine, bilirubin and INR.;Child-Pugh score. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Calculation based on bilirubin, albumin, INR, ascites and encephalopathy.;Serum Creatinine. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Fasting blood test.;Blood Urea Nitrogen. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Fasting blood test.;Serum Total Bilirubin. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Fasting blood test.;Serum albumin. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Fasting blood test.;International Normalized Ratio (INR). Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Fasting blood test.;Aspartate transaminase (AST)/Alanine aminotransferase (ALT) ratio. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Fasting blood test.;Platelet Count. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Fasting blood test.;Fasting Blood Sugar. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Fasting blood test.;Quality of life. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Chronic Liver Disease Questionnaire.;Slim muscle mass. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Bioimpedance machine.	—

Measure

Time frame

Model for End-stage liver disease (MELD) score. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Calculation based on creatinine, bilirubin and INR.;Child-Pugh score. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Calculation based on bilirubin, albumin, INR, ascites and encephalopathy.;Serum Creatinine. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Fasting blood test.;Blood Urea Nitrogen. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Fasting blood test.;Serum Total Bilirubin. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Fasting blood test.;Serum albumin. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Fasting blood test.;International Normalized Ratio (INR). Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Fasting blood test.;Aspartate transaminase (AST)/Alanine aminotransferase (ALT) ratio. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Fasting blood test.;Platelet Count. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Fasting blood test.;Fasting Blood Sugar. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Fasting blood test.;Quality of life. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Chronic Liver Disease Questionnaire.;Slim muscle mass. Timepoint: Beginning of the study, end of the third month, end of the sixth month. Method of measurement: Bioimpedance machine.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzita Hekmatdoost

Shahid Beheshti University of Medical Sciences

a_hekmat2000@yahoo.com+98 21 2237 6470

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026